Multiplexed diagnostics for precision medicine in lung cancer

Abstract

The clinical implementation of genetic profiling for lung cancer is warranted to allow precision medicine for individual lung cancer patients. We currently apply next-generation sequencing (NGS)-based clinical sequencing to detect driver mutations that may inform treatment recommendations in lung cancer. We prospectively applied amplicon sequencing panels and assays to determine variants of ALK, RET, ROS1, and NTRK1 fusion transcripts in patients with lung cancer. We then determined the proportion of patients who received genotype-directed therapy and their overall survival (OS). Tumor FFPE specimens were successfully analyzed by NGS. The OS of patients with advanced or recurrent cancer who had driver mutations followed by targeted therapy was significantly longer than that of patients with no mutations or those with a mutation not treated with targeted therapy. This Kindai Clinical Sequencing for lung cancer patients can assist physicians in matching patients with approved or experimental targeted treatments.